For US residents only.
Click below for answers to some of the most frequently asked questions about KISQALI® (ribociclib).
KISQALI is a once-daily oral prescription medicine taken along with hormone therapy for the treatment of postmenopausal women with hormone receptor-positive (ER+ and/or PR+), HER2- advanced or metastatic breast cancer.
KISQALI is a targeted treatment for HR+ (ER+ and/or PR+), HER2- metastatic breast cancer that blocks, or interferes with, substances that play a key role in cancer cell growth and survival. KISQALI affects cancer cells, but can also affect healthy cells.
Combination therapy is a treatment strategy of taking multiple medicines to help delay disease progression. By combining KISQALI and hormone therapy, you’ll have 2 medicines working differently, but together, to help slow the growth and spread of your metastatic breast cancer.
See results with KISQALI + letrozole here.
The most common side effects of KISQALI are nausea, tiredness, diarrhea, hair loss, vomiting, constipation, headache, and back pain. KISQALI can also cause more serious side effects. Learn more about the potential side effects of KISQALI here.
Although not all side effects can be managed, your health care team may offer suggestions to help manage some of the side effects of KISQALI. It’s important to talk with your doctor or nurse about side effects you experience and the best ways to manage them. Get tips about managing some common side effects here.
KISQALI is a prescription medicine that is a convenient once-daily oral tablet that comes in an easy-to-use blister pack. Your health care provider will prescribe the dose of KISQALI that's right for you. You should take KISQALI exactly as your health care provider tells you. Take KISQALI each day at about the same time, preferably in the morning. Do not change your dose or stop taking KISQALI unless your health care provider tells you. You may take KISQALI with or without food. Ask your doctor about the recommended dose of your hormone therapy. Learn more about taking KISQALI here.
Avoid pomegranate or pomegranate juice, grapefruit or grapefruit juice, and St. John’s Wort (Hypericum perforatum) while taking KISQALI.
The KISQALI FEMARA Co-Pack is a convenient, two-in-one package that includes one 28-day cycle of KISQALI and one 28-day cycle of FEMARA® (letrozole). This combined prescription comes in a single pack and requires a single co-pay that covers both drugs. The KISQALI FEMARA Co-Pack is available in all 3 approved KISQALI dose options: 600 mg (three 200-mg tablets), 400 mg (two 200-mg tablets), and 200 mg (one 200-mg tablet) with FEMARA 2.5 mg.
Novartis Pharmaceuticals Corporation is committed to helping make treatment with KISQALI as affordable as possible. Learn about financial resources here.
KISQALI Care is a comprehensive patient support program that provides those who have been prescribed KISQALI with helpful materials that can be referenced throughout treatment, along with a dedicated navigator who can provide one-on-one assistance. Sign up here.
Yes. The KISQALI Care Patient Support program is completely free to those who have been prescribed KISQALI.
If you take too much KISQALI, call your doctor right away or go to the nearest hospital emergency room. If you miss a dose of KISQALI or vomit after taking a dose of KISQALI, do not take another dose on that day. Take your next dose at your regular time.